

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL **for FY 2001**

Patent fees are subject to annual revision.

TOTAL AMOUNT OF PAYMENT **\$180.00**

Complete if Known

Application Number	09/882186
Filing Date	06/15/2001
First Named Inventor	Khanna et. al.
Examiner Name	Unknown
Group Art Unit	Unknown
Attorney Docket No.	3284/US

METHOD OF PAYMENT

1. ☒ The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to:

Deposit Account Number **19-1025**

Deposit Account Name

☒ Charge Any Additional Fee Required Under 37 CFR §§ 1.16 and 1.17

☐ Applicant claims small entity status. See 37 CFR § 1.27

2. ☐ Payment Enclosed:

☐ Check ☐ Credit card ☐ Money Order ☐ Other

FEE CALCULATION

1. BASIC FILING FEE

Large Entity Code	Small Entity Code	Fee (\$)	Fee (\$)	Fee Description	Fee Paid
101	710	201	355	Utility filing fee	
106	320	206	160	Design filing fee	
107	490	207	245	Plant filing fee	
108	710	208	355	Reissue filing fee	
114	150	214	75	Provisional filing fee	
SUBTOTAL (1)					

2. EXTRA CLAIM FEES

Extra Claims	Fee from below	Fee Paid
Total Claims -20** = 0	X	0.00
Independent Claims -3** = 0	X	0.00
Multiple Dependent		

Large Entity Small Entity

Fee Code (\$)	Fee Code (\$)	Fee (\$)	Fee (\$)	Fee Description	Fee Paid
103	18	203	9	Claims in excess of 20	
102	80	202	40	Independent claims in excess of 3	
104	270	204	135	Multiple dependent claim, if not paid	
109	80	209	40	** Reissue independent claims over original patent	
110	18	210	9	** Reissue claims in excess of 20 and over original patent	
SUBTOTAL (2)					\$0.00

3. ADDITIONAL FEES

Large Entity Code	Small Entity Code	Fee (\$)	Fee (\$)	Fee Description	Fee Paid
105	130	205	65	Surcharge - late filing fee or oath	
127	50	227	25	Surcharge - late provisional filing fee or cover sheet	
139	130	139	130	Non - English specification	
147	2,520	147	2,520	For filing a request for <i>ex parte</i> reexamination	
112	920*	112	920*	Requesting publication of SIR prior to Examiner action	
113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action	
115	110	215	55	Extension for reply within first month	
116	390	216	195	Extension for reply within second month	
117	890	217	445	Extension for reply within third month	
118	1,390	218	695	Extension for reply within fourth month	
128	1,890	228	945	Extension for reply within fifth month	
119	310	219	155	Notice of Appeal	
120	310	220	155	Filing a brief in support of an appeal	
121	270	221	135	Request for oral hearing	
138	1,510	138	1,510	Petition to institute a public use proceeding	
140	110	240	55	Petition to revive - unavoidable	
141	1,240	241	620	Petition to revive - unintentional	
142	1,240	242	620	Utility issue fee (or reissue)	
143	440	243	220	Design issue fee	
144	600	244	300	Plant issue fee	
122	130	122	130	Petitions to the Commissioner	
123	50	123	50	Processing fee under 37 CFR § 1.17(q)	
126	180	126	180	Submission of Information Disclosure Statement	180.00
581	40	581	40	Recording each patent assignment per property (times number of properties)	
146	710	246	355	Filing a submission after final rejection (37 CFR § 1.129(a))	
149	710	249	355	For each additional invention to be examined (37 CFR § 1.129(b))	
179	710	279	355	Request for Continued Examination (RCE)	
169	900	169	900	Request for expedited examination of a design application	
Other fee (specify)					
SUBTOTAL (3)					\$180.00

**or number previously paid, if greater; For Reissues, see above

*Reduced by Basic Filing Fee Paid

SUBMITTED BY **Complete (if applicable)**

Name (Print/Type)	Rachel A. Polster	Registration No. (Attorney/Agent)	47,004	Telephone	636-737-5761
Signature	<i>Rachel A. Polster</i>	Date	11/12/2001		

WARNING: Information on this form may become public. Credit card information should not be included in this form. Provide credit card information and authorization in

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Case C-3284/US

UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF)
)
 Khanna et al.) GROUP ART UNIT: Unknown
)
 SERIAL NO: 09/882,186) EXAMINER: Unknown
)
 FILED: June 15, 2001)
) DATE: November 12, 2001

TITLE: Cycloalkyl Alkanoic Acids as Integrin Receptor Antagonists

I hereby certify that this correspondence is being deposited with the
 United States Postal Service as first class mail in an envelope addressed to:
 Commissioner of Patents and Trademarks,
 Washington D.C., 20231 on November 26, 2001

Rachel A. Polster

Registration No. 47,004

Rachel A. Polster Date: *Nov. 26, 2001*

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR 1.97-1.99

Hon. Commissioner of Patents & Trademarks
 Washington, D.C. 20231

Sir:

This Information Disclosure Statement is filed pursuant to 37 CFR §1.97-1.99, as supplemented by MPEP §609. Attached is PTO Form 1449 listing documents believed to be material to the subject matter claimed in the above-identified application as of the filing date of said application.


Presentation of these documents listed on PTO Form-1449 is not an admission that any listed document is prior art under the Patent Statutes and the right is reserved to antedate any material described in the listed documents by a showing under 37CFR §1.131 or otherwise.

The following patents and publications are listed on PTO Form-1449.

5,741,796	MERCK & CO.	04/21/98
WO 01/14337	MERCK & CO.	03/01/01
WO 01/14338	MERCK & CO.	03/01/01
WO 99/45927	SMITHKLINE	09/16/99
WO 00/38786	G.D. SEARLE & CO.	07/06/00
WO 00/38719	G.D. SEARLE & CO.	07/06/00
WO 00/38715	G.D. SEARLE & CO.	07/06/00
WO 00/38665	G.D. SEARLE & CO.	07/06/00
WO 00/64888	AVENTIS PHARMA.	11/02/00
WO 98/31359	MERCK & CO.	07/23/98
WO 98/20871	NIPPON CHEMIPHAR	05/22/98
WO 96/41795	FUJISAWA PHARMA	12/27/96
WO 95/32710	MERCK & CO.	12/07/95
WO 97/12878	BASF	04/10/97
EP 0 671 392	HOECHST AG	02/21/01
EP 0 478 328	MERCK & CO	01/10/96
WO 93/21166	SMITHKLINE BEECHAM	10/28/93
GB 2 264 115	BRITISH BIO-TECH	08/18/93
JP 10287634	OTSUKA PHARM.	10/27/98

Please charge the appropriate fee to Deposit Account
No. 19-1025.

Respectfully submitted


Rachel A. Polster
Registration No. 47,004
636-737-5761 (St. Louis)
fax 636-737-5452

Pharmacia Corporate Patent Department
800 N. Lindbergh Blvd.
Mail Zone 04E
St. Louis, MO 63167